Among postmenopausal women with osteoporosis, long-term daily use of the estrogen receptor modulator, raloxifene, decreases the risk of new vertebral fractures, according to the results of a randomized trial.
Dr. Pierre D. Delmas from the University Claude Bernard of Lyon, France, and colleagues report findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, in the August issue of the Journal of Clinical Endocrinology and Metabolism. In the trial, 7705 postmenopausal women with osteoporosis were randomly assigned to raloxifene 60 mg/day or 120 mg/day or to placebo.
The researchers looked for new vertebral fractures from radiographs taken at baseline and at 2, 3 and 4 years.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!